Clinical trials: Major Depressive Disorder, completed
Major Depressive Disorder
Genetic Study of Liver Enzymes in Patients With Side Effects From Antidepressants
The objective of this pilot study is to determine the genetic polymorphism rate of CYP450 2D6 and 2C19 metabolic enzymes in patients with significant adverse effects from antidepressants, compared to a population of patients who…
- Trial name
- NCT00360256
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Augusta University
Major Depressive Disorder
Flexible Dose Titration Add-on Study to Treat Major Depressive Disorder
Depressed patients will receive 6 weeks of citaloprma (20-40mg) therapy. Subjects who have an inadequate response (partial or non-responder) will be randomized to receive either mecamylamine (5-10mg) or placebo added to their…
- Trial name
- NCT00593879
- Testing
- Mecamylamine
- Volunteers
- 450 people
- Sponsor
- Targacept Inc.
Major Depressive Disorder
A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder
To evaluate the efficacy, safety, and tolerability of NBI-1070770 compared to placebo on improving symptoms of depression in participants with major depressive disorder (MDD).
- Trial name
- NCT06267846
- Testing
- NBI-1070770
- Where
- 13 sites in United States
- Volunteers
- 73 people
- Sponsor
- Neurocrine Biosciences
Major Depressive Disorder
Canadian Biomarker Integration Network for Depression (CAN-BIND) - Validation Study
This is a validation study that will replicate a completed study designed to assess biomarkers of treatment response to standard antidepressant treatment.
- Trial name
- NCT04162522
- Testing
- Escitalopram, Brexpiprazole
- Where
- 6 sites in Canada
- Volunteers
- 1 people
- Sponsor
- University Health Network, Toronto
Elderly, Major Depression
Depression in the Elderly and Cerebral Amyloid Plaques: Characterization by [18F] AV-45 Affectives Symptoms and Amyloïd Plaques (ASAP)
The primary objective of the study is to compare the brain amyloid load in fully, partially and non remitting depressed elderly patients at 8 weeks of antidepressant therapy, by using PET with [F18]AV45.
- Trial name
- ASAP (NCT01962753)
- Testing
- 18FAV45
- Where
- 10 sites in France
- Volunteers
- 92 people
- Sponsor
- University Hospital, Tours
Depression
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
The purpose of the study is to evaluate the efficacy of study drug (BMS-820836) as compared with continued duloxetine in the treatment of patients with treatment resistant depression (TRD).
- Trial name
- NCT01309945
- Testing
- Duloxetine, BMS-820836
- Where
- 84 sites in United States, Canada and 4 more
- Volunteers
- 889 people
- Sponsor
- Bristol-Myers Squibb
Depression
Study Evaluating Long-Term Safety of Effexor XR in Patients With Major Depression.
Phase III long-term safety study of Effexor XR in patients with major depression.
- Trial name
- NCT00225524
- Testing
- Effexor XR
- Where
- 73 sites in Japan
- Volunteers
- 150 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depressive Disorder, Major
Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder
This multi-centre study will follow a randomised, double-blind, parallel-group, active-controlled design and will evaluate the efficacy, safety and tolerability of bupropion extended-release (XL) (300 mg/day) compared with…
- Trial name
- NCT02191397
- Testing
- Bupropion, Escitalopram
- Where
- 20 sites in China
- Volunteers
- 534 people
- Sponsor
- GlaxoSmithKline
Anxiety Disorders, Depressive Disorders
Antidepressant Safety in Kids Study
This study will evaluate the risks and benefits of treatment with a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor in children and adolescents with a pre-specified anxiety disorder…
- Conditions
- Anxiety Disorders, Depressive Disorders, Eating Disorders, Obsessive Compulsive Disorder
- Trial name
- ASK (NCT00395213)
- Testing
- Selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) medications
- Where
- United States
- Volunteers
- 569 people
- Sponsor
- Duke University
Depressive Disorder, Major, Major Depressive Disorder (MDD)
Sexual Functioning Study With Antidepressants
Effects of two depression medication on sexual functioning
- Trial name
- NCT00316160
- Testing
- Bupropion Hydrochloride Extended-release, Extended-release Venlafaxine
- Where
- 45 sites in United States
- Volunteers
- 347 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms.
- Trial name
- NCT01435759
- Testing
- Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg
- Where
- 82 sites in United States, Argentina and 3 more
- Volunteers
- 1,197 people
- Sponsor
- Shire
Depressive Disorder, Major
Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study
The purpose of this study is to determine the long-term safety and tolerability of vortioxetine, once daily (QD), in participants with major depressive disorder.
- Trial name
- NCT01152996
- Testing
- Vortioxetine
- Volunteers
- 1,075 people
- Sponsor
- Takeda
Depressive Disorder, Major, Asthma
Impact of Caregiver Depression on Asthma in the Child
This study will examine if depression in a primary caregiver is associated with more hospitalization or ER visits in children with asthma.
- Trial name
- NCT00223288
- Testing
- Lexapro
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- University of Texas Southwestern Medical Center
Major Depressive Disorder
Evaluation of the Brainsway Deep Transcranial Magnetic Stimulation (TMS) H-Coil in the Treatment of Major Depression Disorder
The purpose of the study is to evaluate the efficacy and safety of deep brain rTMS, (Transcranial Magnetic Stimulation), a new experimental procedure using the H-Coil, in subjects with Major Depressive Disorder that have been…
- Trial name
- NCT00927173
- Testing
- Brainsway H-Coil Deep TMS System
- Where
- 22 sites in United States, Canada and 3 more
- Volunteers
- 233 people
- Sponsor
- Brainsway
Major Depressive Disorder
Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression
This study will examine the effects of a first-line treatment for major depressive disorder (MDD), interpersonal psychotherapy (IPT), among men and women prisoners.
- Trial name
- NCT01685294
- Testing
- Group IPT for Depression + TAU
- Where
- 5 sites in United States
- Volunteers
- 181 people
- Sponsor
- Brown University
Major Depressive Disorder (MDD)
A Duloxetine Dosing Strategy Study in Korean Patients With Major Depressive Disorder
The purpose of this study is to assess nausea severity in response to four different drug dosing strategies of Duloxetine (30 mg with food, 60 mg with food, 30 mg without food, and 60 mg without food) in Korean patients with…
- Trial name
- NCT00960986
- Testing
- Duloxetine hydrochloride
- Where
- 7 sites in South Korea
- Volunteers
- 249 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder, Posttraumatic Stress Disorder
Comparing Individual Therapies for Veterans With Depression, PTSD, and Panic Disorder
Cognitive behavioral therapy (CBT) is a brief, efficient, and effective treatment for individuals with depressive/anxiety disorders.
- Conditions
- Major Depressive Disorder, Posttraumatic Stress Disorder, Panic Disorder and Agoraphobia
- Trial name
- NCT04293341
- Testing
- Transdiagnostic Behavior Therapy, Cognitive Processing Therapy for PTSD, Cognitive Behavioral Therapy for MDD
- Where
- United States
- Volunteers
- 304 people
- Sponsor
- VA Office of Research and Development
Depressive Disorder, Major
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
This six-week study will evaluate the efficacy, safety and tolerability of GSK561679 compared to placebo in female subjects with major depressive disorder
- Trial name
- NCT00733980
- Testing
- GSK561679
- Where
- 18 sites in United States
- Volunteers
- 150 people
- Sponsor
- GlaxoSmithKline
Unipolar Depression, Bipolar Depression
Investigating tDCS as a Treatment for Unipolar and Bipolar Depression
Transcranial direct current stimulation (tDCS) is a novel treatment approach for depression that has shown promising efficacy in four recent double-blind, randomized, sham-controlled trials (RCT) and a meta-analysis.
- Trial name
- NCT01562184
- Testing
- Soterix tDCS device
- Where
- 6 sites in United States, Australia
- Volunteers
- 120 people
- Sponsor
- The University of New South Wales
Major Depressive Disorder
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Major Depressive Disorder
This study is to evaluate that (SEROQUEL®) quetiapine sustained-release is efficacious and safe in the treatment of patients with MDD.
- Trial name
- MOONSTONE (NCT00320268)
- Testing
- Quetiapine fumarate
- Where
- 37 sites in United States
- Volunteers
- 600 people
- Sponsor
- AstraZeneca